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Abstract. Advances in understanding of the molecular mechanisms underlying oral
squamous cell carcinoma (OSCC) have resulted in an increasing number of
biomarkers that can be used to predict the behaviour of this disease. The authors
conducted a literature review of studies examining the role of
immunohistochemistry-based protein biomarkers in predicting OSCC outcome.
Only articles published in PubMed-indexed journals over the past 5 years were
considered. 22 molecular biomarkers were identified and classified into five groups
based on their biological functions: cell cycle acceleration and proliferation; tumour
suppression and apoptosis; hypoxia; angiogenesis; and cell adhesion and matrix
degradation. The cell cycle acceleration and proliferation biomarkers showed the
most divergent prognostic findings. Studies on tumour suppression and apoptosis
biomarkers were the most prevalent. There were only a few studies examining
molecular biomarkers of hypoxia and angiogenesis, and studies examining cell
adhesion and matrix degradation biomarkers have shown that this group has the
greatest potential for assessing prognostic parameters. Amongst the several proteins
analysed, the immunohistochemical expression levels of epithelial growth factor
receptor (EGFR), p53, and matrix metalloproteinases (MMPs) have demonstrated
the greatest potential for survival prediction in OSCC, but this review demonstrates
that their prognostic relevance is debatable and requires further standardisation.0901-5027/030298 + 10 $36.00/0 # 2010 International Association of Oral and Maxillofacial SurgeL. R. Oliveira, A. Ribeiro-Silva
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results from the multistep accumulation
of heterogeneous genetic changes in squa-
mous cells. These changes progressively
increase the ability of transformed cells to
proliferate and invade54. The heterogene-
ity of these changes explains why tumours
at the same clinical stage and localisationoften show significant differences in
their clinical outcomes and treatment
responses18,21,25.
OSCC remains one of the most difficult
malignancies to control because of its high
propensity for local invasion and cervical
lymph node dissemination18. The biologi-
cal factors that underlie the locoregionaland distant spreading of these neoplasms
are not completely understood56. The
behaviour of OSCC is difficult to predict
solely using conventional clinical and his-
topathological parameters, and due to
location of the disease, the multimodal
tumour therapy usually prescribed leads
to a reduction in quality of life, making theons. Published by Elsevier Ltd. All rights reserved.
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greater than other malignancies54,57. For
these reasons, despite advances in thera-
peutic strategies, the survival rate of
OSCC patients is still poor.
Investigation of phenotypic changes in
OSCC cells may have a strategic prognos-
tic value, and special attention has recently
been focussed on the use of potential
molecular biomarkers as reliable predic-
tors of tumour aggressiveness54. The
assessment of prognostic biomarkers can
also be useful in the selection of patients
who would best benefit from intensive
adjuvant therapy66.
In recent years, the number of molecu-
lar-based assays has increased but histo-
pathology remains the gold standard for
most diagnostic and therapeutic decisions.
Immunohistochemistry (IHC) is a globally
available tool that complements histo-
pathological analysis by detecting gene
expression at the protein level. Advances
in the understanding of cancer at the reg-
ulatory protein expression level have
resulted in the identification of some prog-
nostic tumour biomarkers associated with
the clinical outcome of OSCC, and there
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Tumour suppressor genes, oncogenes,
cell proliferation markers, angiogenic
markers, and cell adhesion molecules have
been studied as potential tools to predict
the prognosis of patients with OSCC54.
An immunohistochemical panel using
multiple prognostic molecular biomarkers
can provide useful information for the
identification of high-risk OSCC patients.
The objective of this study is to identify,
through an extensive review of recently
published literature, the major IHC bio-
markers that have been significantly asso-
ciated with the prognosis of OSCC.
Material and methods
This review investigated the scientific lit-
erature examining the role of the major
biomarkers associated with the clinical
outcome of OSCC over the past 4 years
(June 2005 to June 2009). A web-based
search was performed in the PubMed
database to retrieve studies on this subject.
The search terms were ‘oral cancer’,iomarkers investigated through IHC in OSCC.
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This search was subsequently refined, and
the research manuscripts were then
selected based on the abstract text.
The studies selected for this review
were retrospective investigations focuss-
ing on prognostic and survival parameters
in which IHC was performed in the pri-
mary OSCC tumour. In the selected manu-
scripts, all surgical specimens had been
taken prior to the initiation of radiotherapy
or chemotherapy. The following anatomi-
cal localisations were included in this
review: C00, C02–C06, C06.1, and
C06.226. Reports detailing with in vitro
investigations were excluded from this
review.
Results
The search terms used for this review
identified 22 different molecular biomar-
kers that had been investigated using IHC
to assess prognostic parameters in OSCC
patients. Table 1 demonstrates the prog-
nostic relevance of all tumour biomarkers
divided by group, as well as the variationsc Sample size and P value
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according to each specific marker studied
amongst the different publications. The P
values were obtained from multivariate
Cox regression or Kaplan–Meier analysis
(preferably overall survival) when the first
was lacking. The biomarkers were classi-
fied into five groups based on their biolo-
gical function: cell cycle acceleration and
proliferation; tumour suppression and
apoptosis; hypoxia; angiogenesis; and cell
adhesion and matrix degradation.
Cell cycle acceleration and proliferation
molecules
Five biomarkers were identified belonging
to this group: epithelial growth factor
receptor (EGFR); cyclin D1; Ki-67; pro-
liferating cell nuclear antigen (PCNA);
and serine/threonine kinase 1 (Akt1)
(Table 1).
EGFR (EGF-R, c-erb1–4, Her-2/neu)
EGFR is a transmembrane cell surface
receptor that binds to some ligands such
as EGF and TGF-a, thereby activating the
protein–tyrosine kinase system, which reg-
ulates the signalling involved in cell pro-
liferation and differentiation72. It belongs
to a family of four similar receptors:HER-1
(ErbB1), HER-2 (neu/ErbB2), HER-3
(ErbB3), and HER-4 (ErbB4). EGFR acti-
vation can enhance the malignant potential
of epithelial tissues37. In some studies,
EGFR overexpression had been correlated
with poor prognostic in OSCC
patients2,38,73,74, but these results were
not confirmed in other investigations19,75.
A single study had identified a significant
association between the combined expres-
sion of EGFR, p53, and cyclin D1 and an
unfavourable overall survival (OS) in
OSCC patients72.
Cyclin D1
Tumour cell proliferation is constantly
associated with genetic or epigenetic mod-
ifications in key cell cycle molecules. The
D-type cyclins are expressed during the
progression from G0/G1 to S phase of
the mammalian cell cycle69. Cyclin D1 is
an oncogene that drives cell cycle progres-
sion, and the decision for cell growth or
arrest may depend on the concentration of
cyclin D172. Cyclin D1 amplification is one
of the most frequent molecular alterations
in head and neck squamous cell carcinomas
(HNSCC)81. Cyclin D1 expression alone
has not been associated with OSCC pro-
gression. SHIRAKI et al.72 showed that the
combined expression of cyclin D1, EGFR,and p53 was significantly associated with
an unfavourable OS in OSCC patients.
Similarly, JAYASURYA et al.28 demonstrated
the decreased expression of p16, coupled
with the overexpression of cyclin D1, in
tumours is associated with an unfavourable
clinical outcome.
Ki-67
The expression of the human Ki-67 pro-
tein is strictly connected with cell prolif-
eration. The fact that the Ki-67 protein is
not expressed in G0 resting cells, but is
expressed during all active phases of the
cell cycle (G1, S, G2, and mitosis), makes
it an excellent biomarker for determining
the fraction of actively proliferating cells
in a given tumour8. In an analysis of 113
OSCC patients, MYOUNG et al.57 correlated
the expression of Ki-67 expression with
the cumulative survival rate, confirming
that this biomarker provides useful infor-
mation in predicting a worse prognosis for
OSCC patients. This finding has been
corroborated by other authors73,74, whilst
LEE et al.39 have recently observed no
independent association between Ki-67
expression and OSCC survival.
PCNA
PCNA is a well-known cell cycle marker
protein that plays an important role in
nucleic acid metabolism as a component
of the replication and repair machinery58.
In several recent investigations, PCNA
expression has not been significantly
associated with survival in OSCC
patients32,40,57.
Akt1
Akt plays a pivotal role in cell survival and
proliferation through a number of down-
stream effectors5. Akt overexpression was
an independent and significant indicator of
poor prognosis in a study examining
OSCC outcome40.
Tumour suppression and apoptosis
biomarkers
Five subsets of biomarkers were identified
in this group (Table 1): p53/p63, p21/p27,
Bcl-2 family members, pRb, and Survivin.
p53 and p63
The p53 gene is one of the most studied
biomarkers in OSCC. Functional inactiva-
tion of p53 causes defects in DNA repair
and apoptosis, with a subsequent increase
in genetic instability that can lead to theaccumulation of mutations11. The high
expression of p53 has been associated with
a poor prognosis60–62, and the combined
expression of p53, cyclin D1, and EGFR
has been correlated with an unfavourable
OS in OSCC patients72. The data examin-
ing the prognostic value of the expression
of p63, a p53 homologue, is controversial.
Some authors have found that overexpres-
sion of p63 is associated with better prog-
nosis in OSCC60–62, whilst others have
found the opposite44,47.
p21 and p27
Cell cycle progression is regulated by the
cyclins and cyclin-dependent kinases
(CDKs). The activity of these enzymes
is coordinated by the inhibitory action
of the Cip/Kip family, including both
p21waf1/cip1 and p27Kip1 21. P21waf1/cip1
plays an important function in the regula-
tion of the G1-to-S transition of the cell
cycle, because it is an inhibitor of the
CDKs59. The expression of p27Kip1 can
result in cell cycle arrest or progression,
thereby regulating cell proliferation, cell
motility, and apoptosis. Based on its
post-translational modifications, p27Kip1
can both positively and negatively regulate
these processes. The loss of the expression
or function of these two G1-checkpoint
CDK inhibitors has been implicated in
the progression of many human tumours1.
There are controversial findings concerning
the clinical outcome of p21waf1/cip1-positi-
vite OSCCs 21,59, and no significant asso-
ciation between p27Kip1 expression and
OSCC prognostic has been identified21.
Bcl-2 family members
Bcl-2 family members are apoptosis reg-
ulatory proteins. This family includes both
anti-apoptotic (e.g. Bcl-2, Bcl-X) and pro-
apoptotic proteins (e.g.Bax andBak), and it
is the balance between them that deter-
mines the cell fate9. CAMISASCA et al.9 found
that the expression of Bcl-2, Bax, and Bcl-
X could be correlated with a favourable
outcome in OSCC. dE VICENTE et al.17
demonstrated that Bcl-2 protein expression
was associated with poor prognosis, and
they failed to identify any association
between Bax expression and disease out-
come. Some investigations have shown that
the survival rate was significantly higher in
OSCC patients with Bcl-2-negative and
Bax-positive tumours30,82.
pRb
The Rb pathway plays a crucial regulatory
role in cell cycle progression, and its
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tions. The phosphorylation of pRb occurs
following the activation of CDK4 or
CDK6 through cyclin D1 and results in
its functional inhibition and liberation of
transcription factors required for cell cycle
progression77. Although JAYASURYA
et al.28 have demonstrated a significant
association between pRb overexpression
and reduced disease-free survival (DFS),
SONI et al.76 have shown that OSCCs that
lost pRb expression were aggressive car-
cinomas and had a poor prognosis.
Survivin
Survivin is an inhibitor of apoptosis that
generally is undetectable in normal
mucosa, but is overexpressed in most head
and neck cancers42. LOMUZIO et al.45 iden-
tified Survivin expression as a potential
biomarker of aggressive and invasive
OSCCs.
Hypoxia biomarkers
Four IHC hypoxia biomarkers were iden-
tified as putative prognostic parameters:
hypoxia inducible factor 1a (HIF-1a);
carbonic anhydrase IX (CA IX); glucose
transporter 1 (GLUT-1); and erythropoie-
tin receptor (EPOR).
HIF-1a
HIF-1 is a heterodimeric transcription fac-
tor composed of alpha and beta subunits.
The HIF-1a subunit mediates HIF-1 func-
tion in response to cellular hypoxia. Under
normal oxygen conditions, the HIF-1a
subunit is rapidly degraded by the protea-
some and has a very short half-life. Under
hypoxic conditions, the proteolytic degra-
dation is suppressed, resulting in overex-
pression of this subunit. In response to
decreased oxygen, HIF-1a induces the
transactivation of more than 70 genes
involved in hypoxia adaptation and/or
reversion20,43. The diffuse overexpression
of HIF-1a has been associated with a good
prognosis in OSCC patients20, but some
recent investigations have found the oppo-
site result41,43.
Carbonic anhydrase IX
Carbonic anhydrases (CAs) form a large
family of genes that encode zinc metal-
loenzymes. They are involved in the rever-
sible hydration of carbon dioxide to
carbonic acid, thereby maintaining a
stable intracellular pH. The CAs also par-
ticipate in other biological processes such
as cellular respiration and dystrophic cal-cification25. CA IX is a HIF-1-dependent
member of the CA family and a transmem-
brane glycoprotein involved in pH home-
ostasis68. CHOI et al.13 have shown that CA
IX overexpression is significantly asso-
ciated with disease recurrence and a worse
OS in OSCC patients. KIM et al.32 have
demonstrated a statistically significant
association between high CA IX expres-
sion and a poorer OS in a series of tongue
squamous cell carcinomas. In contrast,
SAKATA et al.68 did not find any association
between CA IX expression and DFS.
GLUT-1
The glucose transporters (GLUT) are also
regulated via the HIF-1 pathway and can
mediate cellular glucose uptake, thereby
perpetuating anaerobic glycolysis25. It has
been suggested that, like CA IX and HIF-
1a, GLUT-1 might represent an endogen-
ous marker of hypoxia34. GLUT has been
identified in diverse human tumours, and
there is some evidence that GLUT-1 is
related to aggressiveness in HNSCC29.
The increased expression of GLUT-1
was significantly associated with a shorter
OS and radiotherapeutic failure in
OSCC34.
EPOR
Erythropoietin (EPO) is a glycoprotein
hormone that mediates the production of
red blood cells. It is synthesised in the
kidney in response to hypoxia, and its
biological effects are regulated through
its interaction with a specific transmem-
brane EPOR and signalling mediated
through HIF-1a3. Head and neck cancer
cells are known to express EPOR3, and
ROH et al.67 have found that high EPOR
expression can be associated with a sig-
nificantly worse prognosis in patients with
oral tongue squamous cell carcinoma.
Angiogenesis biomarkers
Three angiogenic biomarkers were identi-
fied as possible prognostic parameters
(Table 1): vascular endothelial growth
factor (VEGF); endoglin (CD105); and
Eph receptor tyrosine kinases (Ephs).
VEGF
VEGF acts functions mainly as an angio-
genic cytokine that promotes prolifera-
tion, differentiation, and migration of
vascular endothelial cells. It also induces
vessel permeability and promotes
endothelial cell survival by preventing
apoptosis35. One study failed to identifyan independent and significant association
between VEGF expression and prognostic
parameters in patients with OSCC40, but
VEGF overexpression was identified as an
adverse DFS prognosticator in another
investigation4. Two studies confirmed that
patients with VEGF-positive tumours
have significantly poorer survival12,71. In
a meta-analysis carried out on HNSCC
patients (71% of them diagnosed as
OSCC), KYZAS et al.35 demonstrated that
VEGF overexpression was significantly
associated with a worse OS.
CD105
Endoglin is a regulatory component of the
cellular transforming growth factor-b
(TGF-b) receptor complex and can mod-
ulate angiogenesis by the regulation of
different cellular functions including pro-
liferation, differentiation, and migration.
The assessment of neo-vascularisation
using CD105 expression has been consid-
ered a potential predictor of prognosis in
different solid malignancies52. It has been
shown that the evaluation of micro-vessel
density through CD105 expression in pri-
mary OSCC may identify patients at risk
of recurrence of the disease or poor out-
come following treatment12,53. In another
study performed only on biopsies of early
tongue squamous cell carcinomas staged
as T1 or T2, CHUANG et al.14 also demon-
strated that CD105 expression was a sig-
nificant and independent prognostic
predictor of a worse prognosis.
Ephs receptors
Ephs receptors (erythropoietin-producing
human hepatocellular carcinoma) com-
prise the largest family of vertebrate
receptor tyrosine kinases. Together with
their membrane-anchored ephrin ligands
(eph family receptor interacting proteins),
they form a vital cell–cell communication
system capable of bi-directional signal-
ling10. This Eph receptor/ephrin system
has been shown to play a crucial role in
embryonic development, as well as in
several human cancers80. Investigations
suggest that this system can stimulate
invasive behaviour in a tumour, thereby
promoting a more aggressive and meta-
static phenotype10,80. Biochemical and
genetic evidence has also implicated Ephs
receptors as important regulators of angio-
genesis63. In a recent study, SHAO et al.71
showed that a high expression of EphA2
was associated with a shorter survival
period in tongue squamous cell carcinoma
patients.
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molecules
Five IHC matrix degradation and cell
adhesion related molecules were identified
as putative prognostic biomarkers asso-
ciated with OSCC (Table 1): matrix metal-
loproteinases (MMPs), CD44, cadherins,
catenins, and versican.
MMPs
The MMPs are a family of proteases nor-
mally expressed by invasive tumours and
the adjacent stroma16. They are zinc-asso-
ciated endopeptidases capable of degrad-
ing all components of the extracellular
matrix (ECM), as well as the basement
membrane. MMPs have an essential role
in ECM degradation in several situations,
including development, inflammation, tis-
sue repair, and tumour invasion and
metastasis48. There are over 20 known
mammalian MMPs49, and the expression
of MMP family members in OSCC tissues
has been widely reported. Although a
retrospective study with tongue carcino-
mas found no correlation between MMP-2
and MMP-9 overexpression and survi-
val31, there are several conflicting studies
examining the prognostic role of MMPs in
OSCC2,33,39. MMP-9 expression was
associated with poor prognosis in a sub-
group of early stage OSCC patients with-
out neck lymph node metastases16. In
cases of OSCC presenting with lymph
node metastasis, dE VICENTE et al.18 identi-
fied a significant correlation between
MMP-7 and MMP-14 (MT1-MMP)
expression and poor survival. In another
study performed with HNSCC patients
(85% of them diagnosed with OSCC),
LUUKKAA et al.48 found that a high
MMP-13 (collagenase-3) expression level
was significantly associated with a short
survival time.
CD44
The CD44 family is a widely expressed
transmembrane glycoprotein family that
binds hyaluronic acid, growth factors,
and ECM proteins23. The CD44 family
consists of a standard form of CD44
(CD44s) and an alternative splice variant
(CD44v). CD44 has been shown to be a
major factor in cell–cell and cell–ECM
interactions, including cell migration,
adhesion, and some lymphocyte func-
tions33. The low expression of CD44s
on tumour cells has been significantly
correlated with poor prognosis in tongue
carcinomas24, and the absence of CD44v
expression has been associated with ashorter survival time in lip OSSC22. Simi-
larly, KOSUNEN et al.33 has shown that the
irregular expression of CD44 in OSCC
was correlated with poor DFS and OS.
Cadherins
Cadherins are a family of transmembrane
glycoproteins involved in cell–cell adhe-
sion56. In most epithelial cells, this adhe-
sion is established and maintained by the
epithelial-cadherin (E-cad) complex, loca-
lised mainly in the zonula adherens junc-
tions. The cadherin family also includes
more than 20 proteins, such as placental
cadherin (P-cad), that have been described
in several tissues and organs56. E-cad is
expressed in the intercellular junctions of
keratinocytes, whilst P-cad is predomi-
nantly detected on the surface of basal
keratinocytes in the normal epidermis.
Therefore, cells migrating into the supra-
basal compartment tend to down-regulate
P-cad expression46. The loss of adhesion
resulting from the reduced expression of
cadherins can play an important role in
tumour invasion and dissemination49. The
lack of P-cad expression has been asso-
ciated with a low OS rate in OSCC
patients46,56. In contrast, one study failed
to detected an independent and significant
association between E-cad expression and
prognosis40. Some transcriptional repres-
sors have been shown to be important in
the loss of E-cad expression by tumour
cells. The expression of the transcriptional
repressor SIP1, which regulates E-cad
expression, has been correlated with a
lower disease-specific OS in OSCC50.
Catenins
The intercellular domain of E-cad binds to
proteins known as catenins, forming the
cadherin–catenin complex, which is
involved in the intracellular transduction
of cell-to-cell contact signals78. UEDA
et al.78 showed that reduced expression
of b- and g-catenin can be used as a
potential marker of poor OSCC prognosis.
Versican
Versican is one of the main components of
the ECM. It is a chondroitin sulphate
proteoglycan, a member of the aggrecan
gene family, and has been associated with
diverse interactions in a number of biolo-
gical and pathological processes64. Versi-
can is overexpressed in diverse tumours,
and it plays a main role in tumour growth
by repressing cell adhesion, stimulating
cell proliferation and migration, and reg-
ulating angiogenesis65. It has been shownin a cohort of OSCC patients that high
stromal versican expression is an indepen-
dent predictor for an unfavourable prog-
nosis64.
Discussion
In the past few years, significant progress
has been made in the identification and
understanding of prognostic biomarkers
involved in predicting OSCC aggressive-
ness. The TNM classification system can-
not predict the biological features of
tumour cells and, therefore, is unable to
individualise the prognosis. The evalua-
tion of some important prognostic biomar-
kers in OSCC at the time of diagnosis
might allow for the identification of a
subset of patients who require more
aggressive management. Therapeutic
approaches, such as the use of some mole-
cular inhibitors directed against specific
biomarkers along with adjuvant radio-
and/or chemotherapy are promising treat-
ments for OSCC patients.
The main advantage of the identifica-
tion of putative prognostic biomarkers in
OSCC by IHC is the establishment of a
direct association between the morphol-
ogy and these biomarkers, which can aid
in determining their functional relevance.
The use of IHC to evaluate a specific
molecular biomarker has the advantage
of establishing a pattern of expression in
different tumours. IHC can be performed
on formalin-fixed paraffin-embedded spe-
cimens that can be stored for a long time,
thereby allowing retrospective studies of a
large population18.
OSCC carcinogenesis is characterised
by a multistep dysregulation of the cell
cycle machinery. The prognostic signifi-
cance of the expression of biomarkers in
various HNSCC has been extensively stu-
died, but only a few studies have focussed
on OSCC specifically. An extensive array
of IHC biomarkers that have been asso-
ciated with OSCC prognosis is presented
in this review, sometimes with contradic-
tory results. This attests the complexity of
oral carcinogenesis, but variations in the
assessments of some molecular biomar-
kers, as well as some possible methodo-
logical limitations, could also explain
these discrepancies.
The utility of a given biomarker as a
prognostic tool requires a carefully
designed cohort investigation, as well as
the defined criteria to designate a tumour
as negative or positive for a specific IHC
biomarker. Conversely, there is significant
heterogeneity amongst experimental pro-
cedures, and the literature usually gives no
uniform recommendation for a specific
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Table 2. REporting recommendations for tumour MARKer prognostic studies (REMARK)*.
Introduction
1. State the marker examined, the study objectives, and any pre-specified hypotheses.
Materials and methods
Patients
2. Describe the characteristics (e.g., disease stage or co-morbidities) of the study patients,
including their source and inclusion and exclusion criteria.
3. Describe treatments received and how chosen (e.g., randomized or rule-based).
Specimen characteristics
4. Describe type of biological material used (including control samples) and methods of
preservation and storage.
Assay methods
5. Specify the assay method used and provide (or reference) a detailed protocol, including
specific reagents or kits used, quality control procedures, reproducibility assessments,
quantitation methods, and scoring and reporting protocols. Specify whether and how
assays were performed blinded to the study endpoint.
Study design
6. State the method of case selection, including whether prospective or retrospective and
whether stratification or matching (e.g., by stage of disease or age) was used. Specify
the time period from which cases were taken, the end of the follow-up period, and the
median follow-up time.
7. Precisely define all clinical endpoints examined.
8. List all candidate variables initially examined or considered for inclusion in models.
9. Give rationale for sample size; if the study was designed to detect a specified effect size,
give the target power and effect size.
Statistical analysis methods
10. Specify all statistical methods, including details of any variable selection procedures
and other model-building issues, how model assumptions were verified, and how
missing data were handled.
11. Clarify how marker values were handled in the analyses; if relevant, describe methods
used for cutpoint determination.
Results
Data
12. Describe the flow of patients through the study, including the number of patients
included in each stage of the analysis (a diagram may be helpful) and reasons for
dropout. Specifically, both overall and for each subgroup extensively examined
report the numbers of patients and the number of events.
13. Report distributions of basic demographic characteristics (at least age and sex), standard
(disease-specific) prognostic variables, and tumour marker, including numbers of
missing values.
Analysis and presentation
14. Show the relation of the marker to standard prognostic variables.
15. Present univariate analyses showing the relation between the marker and outcome,
with the estimated effect (e.g., hazard ratio and survival probability). Preferably provide
similar analyses for all other variables being analyzed. For the effect of a tumour marker
on a time-to-event outcome, a Kaplan–Meier plot is recommended.
16. For key multivariable analyses, report estimated effects (e.g., hazard ratio) with confidence
intervals for the marker and, at least for the final model, all other variables in the model.
17. Amongst reported results, provide estimated effects with confidence intervals from an
analysis in which the marker and standard prognostic variables are included, regardless
of their statistical significance.
18. If done, report results of further investigations, such as checking assumptions,
sensitivity analyses, and internal validation.
Discussion
19. Interpret the results in the context of the pre-specified hypotheses and other relevant
studies; include a discussion of limitations of the study.
20. Discuss implications for future research and clinical value.
Permission from the publisher to reprint.
* Reprinted from MCSHANE et al. Eur J Cancer 2005: 41: 1690–169655.primary antibody or defines a cut-off for
positivity. In the absence of uniform bio-
logical criteria, scoring categories are
usually chosen arbitrarily. It is possible
that if a scoring criterion is chosen differ-
ently, the correlation with other para-
meters will change. There is also
heterogeneity in the samples amongst
the studies, with distinct stages of disease
in several of them, which frequently leads
to different therapeutic approaches9.
Therefore, differences observed amongst
investigations could be attributed to the
use of distinct methods in the evaluation of
the biomarker expression, as well the het-
erogeneity of the samples. To provide
adequate measures of predictability and
improve the quality of the tumour prog-
nostic biomarkers studies examining
OSCC, the recent guidelines proposed
by REMARK should be considered to
standardise future studies55. Table 2
shows the recommendations for reporting
studies on tumour markers. Specific items
are grouped under the headings: introduc-
tion, materials and methods, results, and
discussion.
TheREMARKreportingguidelineswere
developed to stimulate complete and reli-
able informationonprognostic studies eval-
uating tumour biomarkers. Through this
literature reviewtheauthors found thatmost
research on OSCC is still not following
these recommendations, continuing to pre-
sentheterogeneous results.Besides thenon-
standardised experimental procedures,
some investigations present poor reporting
regarding patient/tumour features, event
numbers, missing data, end and median
follow-up time,and statisticalmethods35,36.
The REMARK guidelines make specific
reporting recommendations for most of
these subjects.
This review highlights some important
gaps in the research on OSCC prognostic
biomarkers. In several studies, there is a
lack of information about their reliability
and clinical relevance. Providing inade-
quate statistical information does not
allow confirmatory studies to be made
on the predictability and correlation mea-
sures, which also makes an adequate meta-
analysis difficult. Other systematic
reviews on prognostic biomarkers were
unable to include data from various inves-
tigations because of poor reporting, ham-
pering assessments on their influence in
different cancers51,66. As shown in Table
1, some studies include a small number of
patients, and the P value was not described
in two studies on cell adhesion and matrix
degradation biomarkers.
Despite these problems, the authors
think that a carefully selected set of bio-markers obtained through further standar-
dised research may help to predict the
prognosis of OSCC patients in future.
For this, the individualized molecular bio-
marker profiles must be analysed in con-
junction with other clinicopathological
information that could better characterise
these tumours and thereby predict the
patient response to treatment.Themolecular biomarkers affecting cell
cycle acceleration and proliferation have
been largely explored in premalignant
lesions from the oral cavity; this is the
most conflicting biomarker group regard-
ing prognostic results. The analysis of
EGFR expression in OSCC is the most
studied, and EGFR has shown prognostic
significance in most investigations.
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nosis of OSCC patients associated with
EGFR overexpression is related to radio-
therapy resistance. No influence on OSCC
survival was found in the studies examin-
ing PCNA expression. This is an unex-
pected finding because PCNA is thought
to represent the proportion of highly pro-
liferative cells in a tumour57.
Considerable therapeutic and prognostic
interest is focussed on regulators of mole-
cular biomarkers associated with tumour
suppression and apoptosis. Amongst these,
most studies point to p53 and the Bcl-2
family members. The p53 and p63 genes
share a similar exon/intron organisation
and have been investigated for prognostic
associations inOSCC62. Despite some con-
tradictory findings implicating high or low
p63 expression with a favourable OSCC
prognosis44,60–62, which could be related to
the opposing functions of its isoforms, p53
and p63 expressionwere significantly asso-
ciated with the prognosis in all selected
studies. In regards to Bcl-2, almost all
studies were consistent with its biological
function and associated high levels ofBcl-2
expression with poor survival in
OSCC17,30,82. This is most likely because
a low level of Bcl-2 usually corresponds to
a high level of Bax, which could promote
tumour cell apoptosis30. The group of bio-
markers associated with tumour suppres-
sion and apoptosis is the most prevalent in
this review, and the high number of sig-
nificant correlations indicates that there are
probably some promising therapeutic tar-
gets to be explored in this group.
Recent studies examining potential bio-
markers in OSCC have focussed on pro-
teins associated with tumour hypoxia.
Hypoxia is a common characteristic of
human solid tumours, and it can drive
malignant cells to undergo adaptive
changes that enable them to survive25,79.
It has been suggested that tumour hypoxia
plays an essential role in promoting chro-
mosome instability, cancer cell invasive-
ness, and metastasis. It is associated with
aggressive tumour growth and treatment
failure in several human solid
tumours20,25,27,37. In agreement with
HOOGSTEEN et al.25, tumour hypoxia is an
important factor that determines the
OSCC response to treatment, but it was
the least investigated molecular biomarker
group in this review. Amongst the main
hypoxia biomarkers found with prognostic
significance in OSCC was HIF-1a7. There
are only a few studies examining the
expression of this biomarker, and based
on the present data, it is difficult to deter-
mine its prognostic relevance. The prog-
nostic characterisation of further tumourhypoxia biomarkers in primary OSCC
could allow for the assessment of biolo-
gical aggressiveness in individual
tumours, as well as establish a more spe-
cific and efficient therapeutic strategy.
Targeted cancer therapy has focussed
on angiogenesis inhibitors. The angio-
genic process plays a key role in creating
a neo-capillary network and is required for
cancer growth, progression, and metasta-
sis53. In spite of the importance of angio-
genesis for tumour development, only a
few studies have been performed examin-
ing the prognostic value of angiogenesis
biomarkers in OSCC. VEGF signalling
has been the most investigated angiogenic
biomarker in OSCC. VEGF plays a crucial
role in the recruitment and maintenance of
the tumour vasculature, and is considered
the major angiogenic factor during carci-
nogenesis and tumour dissemination70,71.
In agreement with a meta analysis carried
out by KYZAS et al.35, despite considerable
diversity in the definition of a VEGF-
positive tumour documented across stu-
dies, VEGF expression can function as a
plausible candidate for the prediction of
OSCC prognosis, because the prognostic
significance of VEGF expression in
patients with OSCC seems to be asso-
ciated with a worse OS4,12,71. Further stu-
dies should be performed, owing to
inconsistent results between tumour
angiogenesis and disease progression in
OSCC, because this discrepancy may be
due to methodological differences includ-
ing the specificity of different endothelial
markers for detecting tumour angiogen-
esis.
Tumour cell progression, invasion, and
migration are dependent on several factors,
including the interaction of malignant cells
with the ECM83. Tumour spread is thought
to require diverse matrix degradation
enzymes and cell adhesion proteins, and
it has been demonstrated that OSCC cells
can synthesise and secrete several of
them49,83. The MMPs were the most inves-
tigated molecular biomarker in this group,
and even though their predictive value in
OSCC remains unclear, it has been
hypothesised that their activities are neces-
sary for tumour angiogenesis, invasion, and
metastatic dissemination49. Owing to this,
some inhibitors specific for MMPs are
being investigated as potential targeted
therapies in the treatment of OSCC83.
Given the potential functional role of the
microenvironment in tumour progression
and prognosis, the expression of some
molecular biomarkers in the OSCC stroma
deserves to be further researched.
The majority of the selected studies in
this present review showed statisticallysignificant associations with OSCC survi-
val. The authors findings are in agreement
with KYZAS et al.36 who have demon-
strated in an important critical review that
almost all investigations examining cancer
prognostic biomarkers highlight only the
statistically significant results. Even so,
the authors identified the subset of candi-
date IHC-based protein predictors of
OSCC, and their findings indicate that
the molecular biomarkers EGFR, p53,
and MMPs have been shown to be promis-
ing prognostic indicators in OSCC, and
the current development of new molecular
targeted anti-cancer agents through gene
therapy or pharmacological intervention is
already being applied6,15,83. These results
need to be further confirmed in additional
powered prospective studies, preferably
performed with larger number of patients,
because the study also revealed important
limitations in areas ranging from the
choice of assayed proteins to the consis-
tency and quality of selected population
and statistical methods used.
The discrepant results presented in this
review indicate that there is an increased
necessity for identification and standardi-
sation of better molecular biomarkers that
can identify OSCC patients with a poor
prognosis. The poor quality of reporting
found, suggests that adherence to the
REMARK recommendations could be
used as a reference to facilitate the stan-
dardisation of future investigations on this
subject. This review demonstrates that
unravelling some potential biomarkers
significantly associated with OSCC pro-
gression across several studies can,
together with clinicopathological evalua-
tion, lead to new target opportunities for
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